- Report
- October 2024
- 189 Pages
Global
From €3244EUR$3,545USD£2,819GBP
€3605EUR$3,939USD£3,132GBP
- Report
- February 2025
- 200 Pages
Global
From €4109EUR$4,490USD£3,570GBP
- Report
- November 2024
- 110 Pages
United States
From €5445EUR$5,950USD£4,731GBP
- Report
- November 2023
- 148 Pages
Global
From €4072EUR$4,450USD£3,538GBP
- Report
- February 2024
- 180 Pages
Global
From €4547EUR$4,969USD£3,951GBP
- Book
- June 2012
- 596 Pages
- Book
- April 2020
- 336 Pages
- Book
- October 2024
North America
- Book
- October 2021
North America
- Book
- September 2018
North America
- Book
- April 2023
North America

Systemic Sclerosis (SSc) is a rare autoimmune disorder that affects the skin, joints, and internal organs. It is characterized by thickening and hardening of the skin, as well as inflammation of the blood vessels. In the context of Allergy and Immunology, SSc is a chronic, progressive disorder that is caused by an abnormal immune response. It is associated with an increased risk of pulmonary hypertension, pulmonary fibrosis, and other complications. Treatment options for SSc include immunosuppressants, biologics, and physical therapy.
The SSc market is a growing segment of the Allergy and Immunology market, with a focus on developing treatments that can improve patient outcomes. Companies in this market include AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Show Less Read more